Intravitreal injection of bevacizumab or ranibizumab for the treatment of pathological myopia choroidal neovascularization / 中华眼底病杂志

ABSTRACT

Objective To compare the efficacy of intravitreal injection of ranibizumab and bevacizumab in the treatment of pathological myopia choroidal neovascularization (PM-CNV).Methods It is a retrospective case study.Seventy-nine patients (79 eyes) with PM-CNV were enrolled in this study.There were 26 males (26 eyes) and 53 females (53 eyes),with the mean age of (30.77 ± 5.53) years.The best corrected visual acuity (BCVA),intraocular pressure,slit lamp microscope,fundus color photography,fundus fluorescein angiography,and optical coherence tomography (OCT) were performed.BCVA was recorded as logarithm of the minimum angle of resolution (logMAR).The central retinal thickness (CMT) was measured by OCT (Cirrus HDOCT).The eyes were divided into bevacizumab treatment group (38 eyes) and ranibizumab treatment group (41 eyes).There was no difference of the mean logMAR BCVA,intraocular pressure and CMT between two groups (t=-0.467,-1.983,1.293;P=0.642,0.051,0.200).The eyes in bevacizumab treatment group were treated with bevacizumab 0.05 ml (1.25 mg),and the eyes in ranibizumab treatment group were treated with ranibizumab 0.05 ml (0.5 rag).Times of injection between two groups were compared.The changes of intraocular pressure were observed at 1,7 days and 1 month after treatment.The changes of logMAR BCVA and CMT at 1,3,6,12 and 24 months after treatment and systemic adverse reactions occur were compared.Results At the 1,3,6,12 and 24 months after treatment,the mean logMAR BCVA of the bevacizumab treatment group and the ranibizumab treatment group was significantly improved than that before treatment (F=132.374,P＜0.01).There was no significant difference in the mean logMAR BCVA at different time points between the two groups (F=0.095,P=0.759).The mean CMT of the two groups was lower than that before treatment (F=151.653,P＜0.01).There was no significant difference in the mean CMT between the two groups (F=0.332,P=0.566).No retinal detachment,endophthalmitis,cataract and persistent high intraocular pressure were associated with drug,injection-related eye and systemic adverse events during follow-up.Seven eyes had conjunctiva bleeding after treatment,11 patients (11 eyes) complained of shadow floaters after treatment.Conclusion Intravitreal injection ofbevacizumab or ranibizumab can equally effectively improve the visual acuity and reduce the CMT of PM-CNV patients.